Dilip S. Shanghvi has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dilip S. Shanghvi, the promoter of Sun Pharma, has filed a routine annual declaration with the stock exchanges under Regulation 31(4) and 31(5) of SEBI's Takeover Regulations. As of 31 March 2025, the promoter along with the promoter group and persons acting in concert have not created any new encumbrance (pledge or lien) on the company's shares, beyond what was already disclosed during FY2024-25. This is a standard year-end compliance filing required from promoters of listed companies. No new shares were pledged or locked in, and existing encumbrances remain as previously reported.
This is a routine compliance disclosure with no material impact on the stock. The absence of any new pledge on promoter holdings is a mildly positive signal, suggesting the promoter group has not needed to use their shares as collateral, which is generally viewed favourably by investors.